The Maharashtra Food and Drug Administration’s latest enforcement figures show a regulator operating at unusually high volume while trying to change how food and medicine safety is governed. Between June 1 and August 31, 2026, the department reported more than 12,000 food inspections, tens of thousands of samples, hundreds of suspended licences and hundreds of arrests. But the more consequential development is the FDA’s attempt to move from periodic crackdowns towards a continuous system built around digital monitoring, business compliance and citizen participation.
That shift matters because food and drug regulation is not a narrow licensing function. It sits inside the everyday infrastructure of cities: the food prepared by caterers, sold by street vendors and served in school canteens; the medicines dispensed by pharmacies; and the consumables used in hospitals. The regulator’s performance therefore depends not only on how many establishments it visits, but also on whether complaints are acted upon, laboratories can process samples, businesses can comply and citizens can identify unsafe practices.
Commissioner Tukaram Mundhe has described the approach through an E3 strategy — Empower, Enable and Enforce. Its stated vision is improved public-health outcomes, with “Safe Food, Safe Drug” as the mission. The three-part framework assigns responsibilities to all sides of the regulatory system: citizens must become more discerning consumers, legitimate businesses must be enabled to comply, and enforcement must target those who disregard safety requirements.
The emphasis on a broader public-health mission reflects a change in the nature of risk. The FDA has linked food consumption patterns to the growing importance of non-communicable diseases such as cancer, cardiac conditions and diabetes. According to the position outlined by Mundhe, high-fat, high-sugar and high-salt food is no longer an occasional concern associated only with festivals. It is part of routine consumption, making food regulation a continuing health issue rather than a seasonal enforcement exercise.
The figures from the three-month period illustrate both the scale of the challenge and the limits of measuring regulatory success through activity alone. The department reported 12,083 food inspections, collection of 37,604 food and drug samples, 5,269 improvement notices and suspension of 603 food licences. It also reported seizure of food stock worth Rs 67.2 crore and 875 arrests in food cases. The source material separately cites 12,000-plus food inspections, more than 4,500 improvement notices and over 600 suspended licences for a recent three-month period, indicating that the figures vary across the department’s cited summaries.
On the drug side, the FDA reported 2,902 inspections and seizure of illegal medicines and cosmetics worth Rs 11.41 crore. Its enforcement against gutkha also produced 644 FIRs, 867 arrests and seizure of banned gutkha and pan masala stocks worth Rs 19.62 crore. The drug wing inspected 607 manufacturing establishments and nearly 2,300 pharmacies. More than 32,000 of over 37,000 collected samples had been tested, according to the figures cited in the report.
These numbers demonstrate reach, but they do not by themselves establish whether the regulatory system is producing safer outcomes. Inspections and seizures are inputs and enforcement outputs. Public-health regulation must also show whether repeat violations decline, whether unsafe products are prevented from reaching consumers, whether corrective notices result in compliance and whether citizens receive timely responses to complaints. The FDA’s proposed digital systems are important precisely because they could connect these separate stages into one traceable process.
The department’s sanctioned strength is 1,271 staff. A roadmap submitted by the commissioner to the government estimates that almost three times that number would be needed to meet expected regulatory norms for Maharashtra’s size and complexity. The FDA’s response is not to wait for a large increase in sanctioned manpower. It is to use digital tools and artificial intelligence to allocate existing capacity more selectively.
The online complaint system can record the location and details of a complaint, assign it to an appropriate officer and set a response deadline. If action is not taken within that period, senior authorities can be alerted automatically. The system also creates an audit trail. This changes the administrative question from whether a complaint was received to whether it was assigned, acted upon and closed within a defined timeframe.
The proposed use of AI is similarly focused on prioritisation rather than replacing officers. The department is looking at combining inspection records, laboratory results, complaints, licensing information and previous violations. Such a system could flag establishments or products requiring greater scrutiny and allow officials to direct limited resources towards higher-risk cases. Mundhe has described the technology as a force multiplier intended to help the regulator “see more, respond faster”.
That model also exposes a central institutional risk: technology can improve visibility and accountability only when the underlying records are complete and consistently maintained. A complaint system that tracks location and deadlines is useful if officers update outcomes, laboratories process samples and licensing information is accurate. Otherwise, digital monitoring may create the appearance of control without closing the regulatory loop. The material supplied does not establish how the system is performing on these measures, so its effectiveness remains a future administrative test rather than a demonstrated result.
Antibiotic misuse shows why enforcement cannot operate in isolation from consumer behaviour and healthcare practices. The FDA has tightened action against pharmacies over the sale of Schedule H drugs without prescriptions and the failure of patients to complete prescribed courses. The department has cancelled and suspended hundreds of pharmacy licences as part of its enforcement efforts. The issue is not limited to individual pharmacies: unscientific antibiotic use can affect treatment practices and public health across the wider urban healthcare system.
The commissioner has also raised concerns about medicine access and hospital pricing. Patients, according to the position cited in the report, should not be forced to purchase medicines exclusively from a hospital’s in-house pharmacy and are free to buy them elsewhere. Hospital consumables such as syringes, saline and other basic disposables have also been flagged because margins may reach as high as 2,000%. The Maharashtra FDA does not directly have the authority to cap those prices, and Mundhe has recommended that the National Pharmaceutical Pricing Authority bring hospital consumables under regulated pricing.
This is an example of how enforcement encounters fragmented authority. A state regulator may identify a pricing or access problem but lack the legal power to resolve it. The issue then moves across institutions, from the state FDA to a national pricing authority. The same fragmentation can affect food safety, where licensing, municipal operations, school administration, public-health departments and consumer behaviour overlap.
The FDA’s action against analogue paneer and its proposals on packaging illustrate another layer of regulation. The department has imposed a one-year ban on the manufacture, storage, distribution and transportation of analogue paneer. It is also working on a proposal to require food-grade, non-toxic ink for newsprint commonly used to wrap street food. These measures link product safety to everyday urban practices, including informal food distribution and packaging waste.
Large gatherings create a similar regulatory challenge. Food prepared at weddings, community events and other functions may be produced outside conventional commercial kitchens, but it can still be consumed by large numbers of people. The FDA has issued compliance guidelines for caterers and event licensees and requires registration for such operations. Treating these activities as part of the regulatory system, rather than leaving them outside it because they are informal or temporary, is a significant administrative change.
The department’s school campaign expands the same logic from enforcement to prevention. Under the “Safe Food for Every School Child” initiative, it conducted 270 workshops involving 60,990 schools across Maharashtra between April 1 and September 11, 2026. The programme addressed nutrition, clean diets and food-safety standards. The FDA also said it had ensured a “No High Fat, Sugar & Salt” requirement within 50 metres of school premises and supported changes in school canteens.
The reported school coverage is substantial, but the available material provides no outcome data on compliance, dietary change or enforcement after the workshops. That distinction is important. Awareness campaigns can extend the reach of a regulator, but they do not substitute for inspections, laboratory capacity or clear accountability. They are most useful when linked to measurable standards and follow-up mechanisms.
The broader lesson from Maharashtra’s enforcement figures is that regulatory capacity is not simply a question of staff numbers. It involves the design of the entire chain: licensing, inspection, sampling, testing, notices, suspensions, prosecution, complaint handling and public communication. The FDA’s E3 strategy attempts to connect these functions, while its digital roadmap seeks to make the chain more visible to senior officials.
The data also shows why the department’s own reporting will matter. Differences between the figures cited for inspections, notices and arrests may reflect different periods or enforcement categories, but consistent definitions are necessary if the public is to assess performance. A high number of inspections can indicate active enforcement, yet it can also conceal uneven coverage, repeated visits to the same establishments or delays between sampling and testing. Transparent, comparable reporting would allow citizens and policymakers to understand not only what the FDA did, but what changed as a result.
For cities, the central question is whether food and medicine safety can become a routine public service rather than a response triggered by festivals, media attention or visible violations. Maharashtra’s regulator is attempting to answer that through three linked measures: stronger enforcement against unsafe or illegal practices, digital systems that make administrative action traceable, and wider participation by businesses, schools and consumers.
The evidence confirms a major increase in reported enforcement activity and a clear attempt to reorganise regulatory work around risk, technology and public awareness. It does not yet establish whether the approach has reduced repeat violations, improved compliance or produced measurable health outcomes. Those indicators, along with the government’s response to the FDA’s manpower roadmap and the proposed pricing and packaging measures, will determine whether the crackdown becomes a durable public-health system or remains a high-volume enforcement phase.